Plasminogen activator inhibitor-1 levels in patients with primary varicose vein

Basit Öğe Kaydı
dc.authoridİmadoğlu Yetkin, Gülay/0000-0002-6115-3583
dc.authoridErdil, Nevzat/0000-0002-8275-840X
dc.authoridCelik, Turgay/0000-0001-8418-0130
dc.authorwosidİmadoğlu Yetkin, Gülay/AAO-2547-2020
dc.authorwosidErdil, Nevzat/K-8079-2019
dc.authorwosidCelik, Turgay/I-2981-2019
dc.contributor.authorErguzel, N.
dc.contributor.authorYetkin, E.
dc.contributor.authorErdem, G.
dc.contributor.authorErdil, N.
dc.contributor.authorYetkin, G.
dc.contributor.authorHeper, G.
dc.contributor.authorCelik, T.
dc.date.accessioned2024-08-04T21:00:10Z
dc.date.available2024-08-04T21:00:10Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim. Plasmin is involved in extracellular matrix remodeling by activating some matrix metallo-proteinases and degrading extracellular matrix; therefore component of fibrinolytic system such as tissue plasminogen activator and plasminogen activators inhibitors (PAI-1) might have a role in the pathogenesis of vascular remodeling. In our study we aimed to investigate the levels of PAI-1 levels in patients with primary varicose veins (VV) and in their age and gender matched control group. Methods. Forty-one consecutive patients with peripheral varicose veins and 37 healthy age and gender-matched control subjects were included in the study from the outpatient cardiology and cardiovascular surgery clinic. Study population consisted of 41 consecutive patients who met the inclusion criteria and diagnosed as having class II primary VV according to CEAP classification. Routine biochemical and hematological analysis were performed in all patients and control subjects. Results. Plasma levels of PAI-1 were found to be lower in patients than those in control subjects (5.19 +/- 2.2 ng/mL vs. 6.47 +/- 2.6 ng/mL, P=0.025). Logistic regression analysis revealed that only the plasma levels of PAI-1 were found to be independently but inversely associated with the presence of primary VVs (Odds ratio: 0.80 CI: 0.64-0.99, P=0.04). Conclusion. We have shown that PAI-1 levels are significantly decreased in patients with pVVs and it has an independent association with the presence of pVVs. However, its exact relation and role via matrix metlalloproteinases on the pathogenesis of the disease remains to be elucidated in further studies. [Int Angiol 2012;31:176-80]en_US
dc.identifier.endpage180en_US
dc.identifier.issn0392-9590
dc.identifier.issue2en_US
dc.identifier.pmid22466984en_US
dc.identifier.startpage176en_US
dc.identifier.urihttps://hdl.handle.net/11616/103862
dc.identifier.volume31en_US
dc.identifier.wosWOS:000304743000012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherEdizioni Minerva Medicaen_US
dc.relation.ispartofInternational Angiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPlasminogen activatorsen_US
dc.subjectExtracellular matrixen_US
dc.subjectFibrinolysinen_US
dc.titlePlasminogen activator inhibitor-1 levels in patients with primary varicose veinen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu